ERBB2 and gastric carcinoma: Naturally, there have been attempts to reproduce this success in other neoplasias that can also show amplification of HER2 (carcinomas of the stomach, bladder, lung etc.).2–4 Finally, in the year 2009, results were presented of the ToGA trial in patients with advanced gastric carcinoma (GC).2